{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-Control&page=9",
    "query": {
      "intervention": "Placebo-Control",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 32914,
    "total_pages": 3292,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-Control&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-Control&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T21:23:59.239Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05107934",
      "title": "Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Pericarditis"
      ],
      "interventions": [
        {
          "name": "RPH-104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "R-Pharm Overseas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-12",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107934"
    },
    {
      "nct_id": "NCT05024916",
      "title": "Blueberry Intervention Study for Brain Aging",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Aging"
      ],
      "interventions": [
        {
          "name": "Intervention",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "65 Years to 89 Years"
      },
      "enrollment_count": 63,
      "start_date": "2022-06-01",
      "completion_date": "2024-10-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05024916"
    },
    {
      "nct_id": "NCT01662206",
      "title": "Probiotics (L. Gasseri, B. Bifidum, B. Longum) on Immune and Intestinal Health in Healthy Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Probiotic",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "65 Years to 80 Years"
      },
      "enrollment_count": 46,
      "start_date": "2012-07",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-04-17",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01662206"
    },
    {
      "nct_id": "NCT03796884",
      "title": "Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenoma",
        "Stage 0 Colorectal Cancer AJCC v8",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage IIA Colorectal Cancer AJCC v8",
        "Stage IIB Colorectal Cancer AJCC v8",
        "Stage IIC Colorectal Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Linaclotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2019-10-30",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03796884"
    },
    {
      "nct_id": "NCT03034772",
      "title": "Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Dorzolamide-timolol",
          "type": "DRUG"
        },
        {
          "name": "Artificial tears",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-02-08",
      "completion_date": "2019-07-05",
      "has_results": true,
      "last_update_posted_date": "2020-06-19",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03034772"
    },
    {
      "nct_id": "NCT04502901",
      "title": "the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Androgenetic Alopecia"
      ],
      "interventions": [
        {
          "name": "KX0826",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Suzhou Kintor Pharmaceutical Inc,",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2020-01-14",
      "completion_date": "2021-01-15",
      "has_results": false,
      "last_update_posted_date": "2021-08-11",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04502901"
    },
    {
      "nct_id": "NCT03396601",
      "title": "NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Depression",
        "Suicidal Ideation"
      ],
      "interventions": [
        {
          "name": "Ketamine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 150,
      "start_date": "2019-06-25",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-01-19",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 2,
      "location_summary": "Hollywood, Florida • Fort Worth, Texas",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03396601"
    },
    {
      "nct_id": "NCT00903201",
      "title": "28 Day Repeat Dose in Cystic Fibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "SB656933",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2009-09-28",
      "completion_date": "2010-12-29",
      "has_results": true,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00903201"
    },
    {
      "nct_id": "NCT01584557",
      "title": "Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Tolvaptan or Samsca",
          "type": "DRUG"
        },
        {
          "name": "placebo or sugar pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cardiovascular Clinical Sciences Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2012-06",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-27",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01584557"
    },
    {
      "nct_id": "NCT01881412",
      "title": "Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "fluticasone",
          "type": "DRUG"
        },
        {
          "name": "Standard Asthma Discharge Instructions",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rhode Island Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 118,
      "start_date": "2012-08",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-10-21T21:23:59.239Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01881412"
    }
  ]
}